Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ISAAC A WATEMBERG

Allopathic & Osteopathic Physicians Family Medicine

NPI
1740241777
CMS profile
78693
Location
FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$53.84

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $53.84 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Medtronic, Inc. $53.84 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ISAAC A WATEMBERG

NPI 1740241777 · CMS profile ID 78693

Allopathic & Osteopathic Physicians / Family Medicine

FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740241777?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ISAAC A WATEMBERG, NPI 1740241777, CMS profile ID 78693. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740241777?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ISAAC A WATEMBERG, NPI 1740241777, CMS profile ID 78693. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740241777?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ISAAC A WATEMBERG, NPI 1740241777, CMS profile ID 78693, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1740241777?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $53.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Medtronic, Inc. $16.4904/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219025429 CMS
Medtronic, Inc. $37.3504/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219025431 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,703.96 4
PY2025 $53.84 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $4,381.89 4
PY2023 Principal investigator $650.82 1
PY2022 Principal investigator $9,072.94 9
PY2021 Principal investigator $1,828,212.33 67
PY2020 Principal investigator $1,246,007.36 33
PY2019 Principal investigator $136,291.28 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,867.65 12/17/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742898583
Principal investigator 1 PFIZER INC. $1,867.65 11/24/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742926527
Principal investigator 1 PFIZER INC. $67,741.95 09/26/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742939451
Principal investigator 1 PFIZER INC. $210,722.91 09/19/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742939445
Principal investigator 1 PFIZER INC. $348,514.71 09/12/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742939431
Principal investigator 1 PFIZER INC. $151,837.31 09/10/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742939449
Principal investigator 1 PFIZER INC. $124,107.72 08/29/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742946233
Principal investigator 1 PFIZER INC. $182.60 08/26/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742942171
Principal investigator 1 PFIZER INC. $135,390.24 08/22/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742945953
Principal investigator 1 PFIZER INC. $101,542.68 08/18/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742946235
Principal investigator 1 PFIZER INC. $1,095.60 07/23/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742942479
Principal investigator 1 SANOFI PASTEUR INC. $1,372.24 07/07/2020 Non-covered Recipient Entity
Ventavia Research Group,LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744017805
Principal investigator 1 PFIZER INC. $14,250.00 07/03/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742939459
Principal investigator 1 PFIZER INC. $53.49 06/24/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742942393
Principal investigator 1 PFIZER INC. $1,016.58 06/24/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742942395
Principal investigator 1 PFIZER INC. $6,795.93 06/04/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742942475
Principal investigator 1 PFIZER INC. $20,785.89 06/04/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742942481
Principal investigator 1 SANOFI PASTEUR INC. $600.00 06/02/2020 Non-covered Recipient Entity
Ventavia Research Group,LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744017773
Principal investigator 1 PFIZER INC. $1,250.00 05/14/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PLACEBOCONTROLLED DOUBLEBLIND RANDOMIZED PARALLEL GROUP PILOT STUDY TO EVALUATE THE EFFICACY OF DEXTROMETHORPHAN HYDROBROMIDE ON ACUTE COUGH IN A PEDIATRIC POPULATION No dispute reported 06/30/2026 742957597
Principal investigator 1 SANOFI PASTEUR INC. $2,909.00 05/14/2020 Non-covered Recipient Entity
Ventavia Research Group,LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744017743
Principal investigator 1 PFIZER INC. $1,245.10 05/07/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742957977
Principal investigator 1 PFIZER INC. $1,500.00 04/21/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 742946123
Principal investigator 1 PFIZER INC. $7,684.00 03/18/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 742946229
Principal investigator 1 PFIZER INC. $3,824.70 02/28/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742958783
Principal investigator 1 PFIZER INC. $7,824.96 02/21/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742959005
Principal investigator 1 PFIZER INC. $300.00 02/20/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742958281
Principal investigator 1 SANOFI PASTEUR INC. $2,183.62 02/06/2020 Non-covered Recipient Entity
Ventavia Research Group,LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744017617
Principal investigator 1 PFIZER INC. $319.77 02/01/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742937049
Principal investigator 1 PFIZER INC. $6,890.73 02/01/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742958415
Principal investigator 1 PFIZER INC. $8,383.65 01/28/2020 Non-covered Recipient Entity
VENTAVIA RESEARCH GROUP LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742958919
Principal investigator 1 PFIZER INC. $3,462.56 01/22/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 742951753
Principal investigator 1 PFIZER INC. $6,925.12 01/08/2020 Non-covered Recipient Entity
Ventavia Research Group LLC
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 742951707
Principal investigator 1 SANOFI PASTEUR INC. $1,559.00 01/07/2020 Non-covered Recipient Entity
Ventavia Research Group,LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744017573